Lonsurf and Onychoclasis - a phase IV clinical study of FDA data

Summary:

Onychoclasis is reported only by a few people who take Lonsurf.

The phase IV clinical study analyzes which people take Lonsurf and have Onychoclasis. It is created by eHealthMe based on reports of 8,061 people who have side effects while taking Lonsurf from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

8,061 people reported to have side effects when taking Lonsurf.
Among them, 4 people (0.05%) have Onychoclasis.

What is Lonsurf?

Lonsurf has active ingredients of tipiracil hydrochloride; trifluridine. eHealthMe is studying from 8,062 Lonsurf users for its effectiveness, alternative drugs and more.

What is Onychoclasis?

Onychoclasis (breaking of the nails) is found to be associated with 968 drugs and 590 conditions by eHealthMe.

Number of Lonsurf and Onychoclasis reports submitted per year:

Gender of people who have Onychoclasis when taking Lonsurf *:

female: 25 %
male: 75 %

Age of people who have Onychoclasis when taking Lonsurf *:

Common drugs people take besides Lonsurf *:

Common side effects people have besides Onychoclasis *:

Fatigue (feeling of tiredness): 4 people, 100.00%
Hair Loss: 2 people, 50.00%
Weakness: 2 people, 50.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 50.00%
Haemoglobin Decreased: 1 person, 25.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 25.00%
Belching (release of gas from the digestive tract): 1 person, 25.00%
Constipation: 1 person, 25.00%
Diarrhea: 1 person, 25.00%
Disease Progression: 1 person, 25.00%

Common conditions people have *:

Colon Cancer: 2 people, 50.00%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 1 person, 25.00%
Colon Cancer Stage Iv: 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lonsurf and have Onychoclasis?

Check whether Onychoclasis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Onychoclasis and when was it recovered:

Onychoclasis in Lonsurf

Expand to all the drugs that have ingredients of tipiracil hydrochloride; trifluridine:

Onychoclasis and drugs with ingredients of tipiracil hydrochloride; trifluridine

Alternative drugs to, pros and cons of Lonsurf:

Lonsurf (8,062 reports)

Common Lonsurf side effects:

Browse all side effects of Lonsurf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Onychoclasis treatments and more:

Onychoclasis (6,496 reports)

COVID vaccines that are related to Onychoclasis:

Common drugs associated with Onychoclasis:

All the drugs that are associated with Onychoclasis:

Onychoclasis (968 drugs)

Common conditions associated with Onychoclasis:

All the conditions that are associated with Onychoclasis:

Onychoclasis (590 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tipiracil hydrochloride; trifluridine (the active ingredients of Lonsurf) and Lonsurf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.